Virtual Network's Login.
ESH Gold Institutional Partner
ESH Gold Institutional Partner
ESH Gold Institutional Partner
The recipient of this annual award will receive a total of 80K€ to finance or co-finance a research project with a focus on MRD in CML and Related Diseases.
The Research Project must:
STAY TUNED FOR THE NEXT CALL FOR APPLICATIONS!
All submitted applications have been peer reviewed independently
by a committee of academic researchers appointed by ESH.
Dept. of Clinical and Biological Science
University of Turin, Italy
For her two-year project on:
“Exploring the potential role of gut microbiota in improving outcomes of chronic myeloid leukemia patients”
“Receiving the John Goldman Award is an extraordinary achievement that fills me with pride, gratitude and motivation. I definitely feel a sense of responsibility in representing the values and standards of this award. The prestige and resources associated with this grant will help me gain new skills and experience.
This award will significantly support my project and career development by enhancing my visibility, providing additional resources and opening up new opportunities for collaboration and advancement.
This recognition strengthens my confidence, also encouraging me to take on more ambitious projects.”
For her two-year project on:
”Comprehensive and sensitive genomic characterisation of diverse mutation types associated with treatment resistance for patients with CML using an RNA-based model”
“My project will hopefully help pave the path for genomic interrogation of CML patients at diagnosis so for the merits of the project to be recognized and awarded the John Goldman prize is a huge honour.
This successful completion of this work will be beyond helpful in aiding
my future research career in haematology.”
For her two year project on
“Biological significance of BCR-ABL1 clonal hematopoiesis
in Ph-positive acute lymphoblastic leukemia (Ph+ ALL):
relevance for treatment-free remission“
“I am very honored and grateful to receive the 2021 John Goldman Research Award. Our project on Ph+ ALL stems from previous observations of presence of residual, non-lymphoblastic, BCR-ABL1+ cells in patients in continuous complete remission, challenging the significance of BCR-ABL1-based MRD in Ph+ ALL. This support from the European School of Hematology will allow us to develop single-cell omics approaches in order to decipher the clonal architecture of Ph+ ALL, which will impact on therapeutic management of these patients.”
For her two year project on
“High dimensional single cell analysis to predict TFR at the time of CML diagnosis”
“I am honoured and thankful to be chosen as the recipient of the John Goldman Research Award this year. Our project aims to interrogate diagnostic CML bone marrow samples using the latest single-cell approaches, and identify patients who will have durable treatment free responses. By integrating the results of our analyses with established clinical workflows, we hope to develop a test that can reliably predict the outcome of TKI discontinuation. This prestigious award from the European School of Haematology offers us the opportunity to leverage cutting-edge technologies toward our long-term goal of developing curative approaches for patients with CML.”
For her two year project on
“Use of machine learning to integrate clinical data and biomarkers to optimise prediction of TFR”
“It is an honour and a pleasure to be the first John Goldman Research Prize Awardee. Receiving funding support from the European School of Haematology (ESH) is a privilege. It represents a critical step in my career towards becoming an independent investigator and provides the opportunity to build new collaborations. My project aims to identify bioassays that can be integrated with clinical data in a machine learning system to develop a personalized predictive model for treatment free remission (TFR). I expect it will bring novel insights into the biology of TFR, opening new horizons toward the discovery of targeted therapies and improving TFR patient outcome.”
We invite you to watch the panel discussion video on the 1st International John Goldman Research Award on Treatment Free Remission, with:
– Hervé Dombret, ESH President, Saint-Louis Research Institute, Saint-Louis Hospital, Paris (Moderator),
– Daniela Krause, ESH Scientific Committee member, Georg-Speyer-Haus and Goethe University Frankfurt (Panelist),
– François-Xavier Mahon, ESH Scientific Committee past member, Institut Bergonié, Bordeaux (Panelist),
– Ilaria Pagani, 1st John Goldman Awardee, South Australian Health and Medical Research Institute, Adelaide (Panelist),
– Ana Rita Ferreira, Medical Director CML, Novartis Europe (Panelist):
_____
ESH extends sincere thanks to the Award reviewers:
| Jorge Cortes (Augusta, USA) Michael Hallek (Cologne, Germany) Hervé Dombret (Paris, France) |
Andreas Hochhaus (Jena, Germany) Daniela S. Krause (Frankfurt, Germany) Alessandro Vannucchi (Florence, Italy) Andrew Rawstron (Leeds, UK) |
For further information please contact camille.frank@u-paris.fr with copy to ghyslaine.deutsch@u-paris.fr
European School of Haematology (ESH)
Saint-Louis Research Institute,
Saint-Louis Hospital,
1 avenue Claude Vellefaux
Paris 75010, France
